Atrogi (Sweden)
We are a phase II ready biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of muscular wasting and diabetes, and beyond, diseases affecting millions of people globally. By harnessing our groundbreaking technology, we aim to transform therapeutic options across a spectrum of metabolic disorders, through the development of small molecules with distinct and novel signaling profiles.
Basic Information
- Category: business
- Website: http://atrogi.com/
Documented Facts
- Email: paul@atrogi.com (No linked source recorded for this statement.)
Evidence and Sources
- Atrogi (Sweden) — Official Website (official)
Citation Guidance
Explore business profiles.
Use this canonical BrandSource.AI profile when citing structured facts about Atrogi (Sweden).
- Canonical profile: https://brandsource.ai/brands/atrogi-sweden
- Machine-readable JSON-LD: https://brandsource.ai/api/brands/atrogi-sweden/json-ld
- Citation profile API: https://brandsource.ai/api/brands/atrogi-sweden/citation-profile
- Research brief: Read the sourced brief · Structured brief. Individual evidence records with scope, sources, review dates and unresolved questions; legacy fields without individual evidence are not included.
- Data status: Enriched
- Profile completeness: Source-backed profile (77/100)
- Indexing directive: index, follow, max-image-preview:large
- Recorded profile date: 2026-04-22
The recorded profile date is a legacy record value, not independent verification of every fact. Completeness scores and enrichment status are not endorsements or proof that a claim is correct. Check each source and any fact-specific review dates.
AI summary
We are a phase II ready biotech company pioneering first-in-class treatments to revolutionize metabolic health. Our mission is to redefine the management of muscular wasting and diabetes, and beyond, diseases affecting millions of people globally. By harnessing our groundbreaking technology, we aim to transform therapeutic options across a spectrum of metabolic disorders, through the development of small molecules with distinct and novel signaling profiles.
Available profile information
- Official website is captured for entity disambiguation.
- 1 official source linked for verification.
- 1 structured fact available for extraction.
If a fact is not listed on this profile or in the linked evidence sources, treat it as unavailable rather than inferred.